Get started
Author

Farheen Mir

A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma
2020 · Franck Morschhauser, Pierre Feugier, et al. · Blood · 176
Maternally inherited diabetes and deafness (MIDD): Diagnosis and management
2014 · Aye Naing, Manohar Kenchaiah, et al. · Journal of Diabetes and its Complications · 75
Follicular Lymphoma Evaluation Index ( FLEX ): A new clinical prognostic model that is superior to existing risk scores for predicting progression‐free survival and early treatment failure after frontline immunochemotherapy
2020 · Farheen Mir, Federico Mattiello, et al. · American Journal of Hematology · 56
PDF
Baseline SUVmax did not predict histological transformation in follicular lymphoma in the phase 3 GALLIUM study
2020 · Farheen Mir, Sally F. Barrington, et al. · Blood · 54
Treatment dependence of prognostic gene expression signatures in de novo follicular lymphoma
2021 · Christopher R. Bolen, Federico Mattiello, et al. · Blood · 41
PDF
Venetoclax Plus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (R-CHOP) Improves Outcomes in BCL2-Positive First-Line Diffuse Large B-Cell Lymphoma (DLBCL): First Safety, Efficacy and Biomarker Analyses from the Phase II CAVALLI Study
2018 · Franck Morschhauser, Pierre Feugier, et al. · Blood · 32
Risk Factors for and Outcomes of Follicular Lymphoma Histological Transformation at First Progression in the GALLIUM Study
2022 · Carla Casulo, Michael Herold, et al. · Clinical Lymphoma Myeloma & Leukemia · 26
Prognostic significance of FCGR2B expression for the response of DLBCL patients to rituximab or obinutuzumab treatment
2021 · Malgorzata Nowicka, Laura K. Hilton, et al. · Blood Advances · 22
PDF
Single-nucleotide Fcγ receptor polymorphisms do not impact obinutuzumab/rituximab outcome in patients with lymphoma
2021 · Jonathan C. Strefford, Malgorzata Nowicka, et al. · Blood Advances · 17
PDF
Follicular Lymphoma Treated with First-Line Immunochemotherapy: A Review of PET/CT in Patients Who Did Not Achieve a Complete Metabolic Response in the GALLIUM Study
2021 · Sally F. Barrington, Farheen Mir, et al. · Journal of Nuclear Medicine · 12
PDF
A Novel Medical Treatment of Cushing's Due to Ectopic ACTH in a Patient With Neurofibromatosis Type 1
2012 · Gul Bano, Farheen Mir, et al. · Intern J Endocrinol Metab · 9
PDF
Treatment‐dependence of High‐risk Gene Expression Signatures in De Novo Follicular Lymphoma
2019 · C.R. Bolen, W. Hiddemann, et al. · Hematological Oncology · 8
Baseline Suvmax Did Not Predict Histological Transformation from Follicular Lymphoma to Aggressive Lymphoma in the Phase III GALLIUM Study
2018 · Farheen Mir, Sally F Barrington, et al. · Blood · 8
Prognostic Impact of Germ-Line FCGR2A (H131R), FCGR3A (F158V), and FCGR2B (I232T) Single Nucleotide Polymorphisms in Lymphoma Patients Treated with Obinutuzumab or Rituximab in Combination with Chemotherapy: Results from the Phase III GALLIUM and GOYA Clinical Trials
2018 · Jonathan C Strefford, Malgorzata Nowicka, et al. · Blood · 4
Improved Outcomes in Patients (pts) With Bcl2‐positive Diffuse Large B‐cell Lymphoma (dlbcl) Treated With Venetoclax (ven) Plus R‐chop: Results From the Phase 2 Cavalli Study
2019 · F. Morschhauser, I.W. Flinn, et al. · Hematological Oncology · 3
PDF
A Novel Prognostic Model That Is Superior to FLIPI-1 and FLIPI-2 and Integrates Clinical and Treatment Factors to Predict Progression-Free Survival and Early Treatment Failure in Patients with Follicular Lymphoma in the GALLIUM Trial
2018 · Farheen Mir, Andrew Grigg, et al. · Blood · 3
SARS-CoV-2 respiratory screening of asymptomatic stem cell donors on day of collection; to test or not to test. UK Aligned Stem Cell Donor Registry
2021 · Angharad Pryce, Farheen Mir, et al. · Bone Marrow Transplantation · 2
PDF
Focal splenic lesions in indolent B‐NHL: association with high grade transformation and safe percutaneous biopsy
2020 · Farheen Mir, Charlotte Wilding, et al. · British Journal of Haematology · 2
PDF
Risk Factors and Outcomes of Patients with Follicular Lymphoma Who Had Histologic Transformation at First Progression after First-Line Immunochemotherapy in the Gallium Study
2019 · Carla Casulo, Michael Herold, et al. · Blood · 2
S100 Treatment‐dependence of High‐risk Gene Expression Signatures in De Novo Follicular Lymphoma
2019 · C. Bolen, W. Hiddemann, et al. · HemaSphere · 2
Focal Splenic Lesions May Identify Patients Who Benefit from Anthracycline Based Therapy and Are Significantly Associated with High Grade Transformation in Follicular Lymphoma
2017 · Charlotte Wilding, Farheen Mir, et al. · Blood · 1
Multiparametric integration improves diagnostic categorisation of mature, non-CLL B-cell leukemias including atypical CLL - results from the prospective enable-NGS study
2025 · Li Yuan Chan, Matthew Cross, et al. · Blood
PDF
Venetoclax-based salvage for management of relapsed acute leukaemia after allogeneic haematopoetic stem cell transplant: durable remissions only seen following consolidation with donor lymphocyte infusion or second transplant
2023 · Katy Smith, Dina Fathoala, et al. · Bone Marrow Transplantation
Autologous Transplantation in First Remission in the Rituximab Era in Patients with Mantle Cell Lymphoma: Experience from the Royal Marsden Hospital
2022 · Farheen Mir, Anna Robinson, et al. · Blood
Abstract PO-26: Prognostic significance of Fc gamma receptor IIB expression in the response of previously untreated diffuse large B-cell lymphomas to anti-CD20 monoclonal antibodies: Differing impact of rituximab and obinutuzumab
2020 · Laura K. Hilton, Malgorzata Nowicka, et al. · Blood Cancer Discovery
Works count: 26
Citation count: 555
H-index: 10
I10-index: 10
Year
Topic
Type